JP2024015430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024015430A5 JP2024015430A5 JP2023212021A JP2023212021A JP2024015430A5 JP 2024015430 A5 JP2024015430 A5 JP 2024015430A5 JP 2023212021 A JP2023212021 A JP 2023212021A JP 2023212021 A JP2023212021 A JP 2023212021A JP 2024015430 A5 JP2024015430 A5 JP 2024015430A5
- Authority
- JP
- Japan
- Prior art keywords
- addiction
- therapeutic agent
- antagonists
- composition
- addictive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012335 Dependence Diseases 0.000 claims 29
- 239000003814 drug Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 11
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 claims 9
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 claims 6
- 108010037622 Type 7 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 6
- 102000010984 Type 7 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 6
- 239000002464 receptor antagonist Substances 0.000 claims 6
- 229940044551 receptor antagonist Drugs 0.000 claims 6
- 102100024233 High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Human genes 0.000 claims 4
- 101001117267 Homo sapiens High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A Proteins 0.000 claims 4
- 101001117266 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 7B Proteins 0.000 claims 4
- 208000030990 Impulse-control disease Diseases 0.000 claims 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 4
- 102100024232 cAMP-specific 3',5'-cyclic phosphodiesterase 7B Human genes 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 claims 3
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 claims 3
- 206010067947 Compulsive sexual behaviour Diseases 0.000 claims 3
- 230000003474 anti-emetic effect Effects 0.000 claims 3
- 230000003556 anti-epileptic effect Effects 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 3
- 239000000935 antidepressant agent Substances 0.000 claims 3
- 229940005513 antidepressants Drugs 0.000 claims 3
- 239000002111 antiemetic agent Substances 0.000 claims 3
- 229940125683 antiemetic agent Drugs 0.000 claims 3
- 229960003965 antiepileptics Drugs 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- -1 metapon Chemical compound 0.000 claims 3
- 239000003887 narcotic antagonist Substances 0.000 claims 3
- 239000004031 partial agonist Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229960001797 methadone Drugs 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims 1
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- DVWTWOHVDUVPJV-JTQLQIEISA-N 2-n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-7-methyl-4-n-(1-methylimidazol-4-yl)thieno[3,2-d]pyrimidine-2,4-diamine Chemical compound N([C@@H](C)C=1N=CC(F)=CN=1)C(N=C1C(C)=CSC1=1)=NC=1NC1=CN(C)C=N1 DVWTWOHVDUVPJV-JTQLQIEISA-N 0.000 claims 1
- IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 claims 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 244000025254 Cannabis sativa Species 0.000 claims 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 1
- 208000001836 Firesetting Behavior Diseases 0.000 claims 1
- 208000001613 Gambling Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical group C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 1
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims 1
- FRPRNNRJTCONEC-UHFFFAOYSA-N Ohmefentanyl Chemical group C=1C=CC=CC=1N(C(=O)CC)C(C(C1)C)CCN1CC(O)C1=CC=CC=C1 FRPRNNRJTCONEC-UHFFFAOYSA-N 0.000 claims 1
- 229940127450 Opioid Agonists Drugs 0.000 claims 1
- 239000008896 Opium Substances 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- 206010034158 Pathological gambling Diseases 0.000 claims 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 claims 1
- 229950005506 acetylmethadol Drugs 0.000 claims 1
- XBMIVRRWGCYBTQ-UHFFFAOYSA-N acetylmethadol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-UHFFFAOYSA-N 0.000 claims 1
- 229960001391 alfentanil Drugs 0.000 claims 1
- KGYFOSCXVAXULR-UHFFFAOYSA-N allylprodine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)CC1CC=C KGYFOSCXVAXULR-UHFFFAOYSA-N 0.000 claims 1
- 229950004361 allylprodine Drugs 0.000 claims 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 claims 1
- 229960001349 alphaprodine Drugs 0.000 claims 1
- UVAZQQHAVMNMHE-XJKSGUPXSA-N alphaprodine Chemical compound C=1C=CC=CC=1[C@@]1(OC(=O)CC)CCN(C)C[C@@H]1C UVAZQQHAVMNMHE-XJKSGUPXSA-N 0.000 claims 1
- 229960002512 anileridine Drugs 0.000 claims 1
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims 1
- 229960004046 apomorphine Drugs 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 1
- 229960004611 bezitramide Drugs 0.000 claims 1
- FLKWNFFCSSJANB-UHFFFAOYSA-N bezitramide Chemical compound O=C1N(C(=O)CC)C2=CC=CC=C2N1C(CC1)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 FLKWNFFCSSJANB-UHFFFAOYSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229950004689 carfentanil Drugs 0.000 claims 1
- YDSDEBIZUNNPOB-UHFFFAOYSA-N carfentanil Chemical compound C1CN(CCC=2C=CC=CC=2)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 YDSDEBIZUNNPOB-UHFFFAOYSA-N 0.000 claims 1
- GPZLDQAEBHTMPG-UHFFFAOYSA-N clonitazene Chemical compound N=1C2=CC([N+]([O-])=O)=CC=C2N(CCN(CC)CC)C=1CC1=CC=C(Cl)C=C1 GPZLDQAEBHTMPG-UHFFFAOYSA-N 0.000 claims 1
- 229950001604 clonitazene Drugs 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 231100000867 compulsive behavior Toxicity 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229950003851 desomorphine Drugs 0.000 claims 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 claims 1
- 229960003701 dextromoramide Drugs 0.000 claims 1
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 1
- 229960003461 dezocine Drugs 0.000 claims 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- RXTHKWVSXOIHJS-UHFFFAOYSA-N diampromide Chemical compound C=1C=CC=CC=1N(C(=O)CC)CC(C)N(C)CCC1=CC=CC=C1 RXTHKWVSXOIHJS-UHFFFAOYSA-N 0.000 claims 1
- 229950001059 diampromide Drugs 0.000 claims 1
- 229960000920 dihydrocodeine Drugs 0.000 claims 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 1
- BRTSNYPDACNMIP-FAWZKKEFSA-N dihydroetorphine Chemical compound O([C@H]1[C@@]2(OC)CC[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O BRTSNYPDACNMIP-FAWZKKEFSA-N 0.000 claims 1
- RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 claims 1
- 229950011187 dimenoxadol Drugs 0.000 claims 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 1
- 229950004655 dimepheptanol Drugs 0.000 claims 1
- CANBGVXYBPOLRR-UHFFFAOYSA-N dimethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)C)C1=CC=CS1 CANBGVXYBPOLRR-UHFFFAOYSA-N 0.000 claims 1
- 229950005563 dimethylthiambutene Drugs 0.000 claims 1
- 229950008972 dioxaphetyl butyrate Drugs 0.000 claims 1
- LQGIXNQCOXNCRP-UHFFFAOYSA-N dioxaphetyl butyrate Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)OCC)CCN1CCOCC1 LQGIXNQCOXNCRP-UHFFFAOYSA-N 0.000 claims 1
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 1
- 229960002500 dipipanone Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims 1
- 229950010920 eptazocine Drugs 0.000 claims 1
- WGJHHMKQBWSQIY-UHFFFAOYSA-N ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 claims 1
- 229960000569 ethoheptazine Drugs 0.000 claims 1
- MORSAEFGQPDBKM-UHFFFAOYSA-N ethylmethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)CC)C1=CC=CS1 MORSAEFGQPDBKM-UHFFFAOYSA-N 0.000 claims 1
- 229950006111 ethylmethylthiambutene Drugs 0.000 claims 1
- 229960004578 ethylmorphine Drugs 0.000 claims 1
- PXDBZSCGSQSKST-UHFFFAOYSA-N etonitazene Chemical compound C1=CC(OCC)=CC=C1CC1=NC2=CC([N+]([O-])=O)=CC=C2N1CCN(CC)CC PXDBZSCGSQSKST-UHFFFAOYSA-N 0.000 claims 1
- 229950004538 etonitazene Drugs 0.000 claims 1
- 229950004155 etorphine Drugs 0.000 claims 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- WTJBNMUWRKPFRS-UHFFFAOYSA-N hydroxypethidine Chemical compound C=1C=CC(O)=CC=1C1(C(=O)OCC)CCN(C)CC1 WTJBNMUWRKPFRS-UHFFFAOYSA-N 0.000 claims 1
- 229950008496 hydroxypethidine Drugs 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000015046 intermittent explosive disease Diseases 0.000 claims 1
- 229960003029 ketobemidone Drugs 0.000 claims 1
- 206010023461 kleptomania Diseases 0.000 claims 1
- RCYBMSQOSGJZLO-BGWNEDDSSA-N levophenacylmorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CC(=O)C1=CC=CC=C1 RCYBMSQOSGJZLO-BGWNEDDSSA-N 0.000 claims 1
- 229950007939 levophenacylmorphan Drugs 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims 1
- 229950010274 lofentanil Drugs 0.000 claims 1
- FQXXSQDCDRQNQE-UHFFFAOYSA-N markiertes Thebain Natural products COC1=CC=C2C(N(CC3)C)CC4=CC=C(OC)C5=C4C23C1O5 FQXXSQDCDRQNQE-UHFFFAOYSA-N 0.000 claims 1
- 229960000365 meptazinol Drugs 0.000 claims 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 1
- 229950009131 metazocine Drugs 0.000 claims 1
- YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 claims 1
- 229950006080 metopon Drugs 0.000 claims 1
- NPZXCTIHHUUEEJ-CMKMFDCUSA-N metopon Chemical compound O([C@@]1(C)C(=O)CC[C@@H]23)C4=C5[C@@]13CCN(C)[C@@H]2CC5=CC=C4O NPZXCTIHHUUEEJ-CMKMFDCUSA-N 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229960000805 nalbuphine Drugs 0.000 claims 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 claims 1
- 229960004300 nicomorphine Drugs 0.000 claims 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229950011519 norlevorphanol Drugs 0.000 claims 1
- 229960004013 normethadone Drugs 0.000 claims 1
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims 1
- 229950006134 normorphine Drugs 0.000 claims 1
- 229950007418 norpipanone Drugs 0.000 claims 1
- WCDSHELZWCOTMI-UHFFFAOYSA-N norpipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CCN1CCCCC1 WCDSHELZWCOTMI-UHFFFAOYSA-N 0.000 claims 1
- 229960004708 noscapine Drugs 0.000 claims 1
- 239000003402 opiate agonist Substances 0.000 claims 1
- 229960001027 opium Drugs 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 229960001789 papaverine Drugs 0.000 claims 1
- 229960005301 pentazocine Drugs 0.000 claims 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 1
- 229960000482 pethidine Drugs 0.000 claims 1
- LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 claims 1
- 229950004540 phenadoxone Drugs 0.000 claims 1
- CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 claims 1
- 229950011496 phenomorphan Drugs 0.000 claims 1
- 229960004315 phenoperidine Drugs 0.000 claims 1
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 1
- PXXKIYPSXYFATG-UHFFFAOYSA-N piminodine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCNC1=CC=CC=C1 PXXKIYPSXYFATG-UHFFFAOYSA-N 0.000 claims 1
- 229950006445 piminodine Drugs 0.000 claims 1
- IHEHEFLXQFOQJO-UHFFFAOYSA-N piritramide Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 IHEHEFLXQFOQJO-UHFFFAOYSA-N 0.000 claims 1
- 229960001286 piritramide Drugs 0.000 claims 1
- 229950004345 properidine Drugs 0.000 claims 1
- XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 201000004645 pyromania Diseases 0.000 claims 1
- 229960003394 remifentanil Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 229960004739 sufentanil Drugs 0.000 claims 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 1
- 229930003945 thebaine Natural products 0.000 claims 1
- FQXXSQDCDRQNQE-VMDGZTHMSA-N thebaine Chemical compound C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(OC)C5=C4[C@@]21[C@H]3O5 FQXXSQDCDRQNQE-VMDGZTHMSA-N 0.000 claims 1
- 229960001402 tilidine Drugs 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024151513A JP2024170507A (ja) | 2010-11-08 | 2024-09-03 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41143110P | 2010-11-08 | 2010-11-08 | |
| US41143710P | 2010-11-08 | 2010-11-08 | |
| US61/411,431 | 2010-11-08 | ||
| US61/411,437 | 2010-11-08 | ||
| US201161482994P | 2011-05-05 | 2011-05-05 | |
| US61/482,994 | 2011-05-05 | ||
| JP2020183616A JP2021014461A (ja) | 2010-11-08 | 2020-11-02 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2022130095A JP2022159477A (ja) | 2010-11-08 | 2022-08-17 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130095A Division JP2022159477A (ja) | 2010-11-08 | 2022-08-17 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024151513A Division JP2024170507A (ja) | 2010-11-08 | 2024-09-03 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024015430A JP2024015430A (ja) | 2024-02-01 |
| JP2024015430A5 true JP2024015430A5 (https=) | 2024-09-11 |
Family
ID=48607500
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537915A Pending JP2014504271A (ja) | 2010-11-08 | 2011-11-07 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2015002909A Pending JP2015071648A (ja) | 2010-11-08 | 2015-01-09 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2016095809A Withdrawn JP2016145255A (ja) | 2010-11-08 | 2016-05-12 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2018000537A Withdrawn JP2018048213A (ja) | 2010-11-08 | 2018-01-05 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2019058230A Pending JP2019094352A (ja) | 2010-11-08 | 2019-03-26 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2020183616A Withdrawn JP2021014461A (ja) | 2010-11-08 | 2020-11-02 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2022130095A Withdrawn JP2022159477A (ja) | 2010-11-08 | 2022-08-17 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2023212021A Pending JP2024015430A (ja) | 2010-11-08 | 2023-12-15 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2024151513A Pending JP2024170507A (ja) | 2010-11-08 | 2024-09-03 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
Family Applications Before (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537915A Pending JP2014504271A (ja) | 2010-11-08 | 2011-11-07 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2015002909A Pending JP2015071648A (ja) | 2010-11-08 | 2015-01-09 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2016095809A Withdrawn JP2016145255A (ja) | 2010-11-08 | 2016-05-12 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2018000537A Withdrawn JP2018048213A (ja) | 2010-11-08 | 2018-01-05 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2019058230A Pending JP2019094352A (ja) | 2010-11-08 | 2019-03-26 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2020183616A Withdrawn JP2021014461A (ja) | 2010-11-08 | 2020-11-02 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
| JP2022130095A Withdrawn JP2022159477A (ja) | 2010-11-08 | 2022-08-17 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024151513A Pending JP2024170507A (ja) | 2010-11-08 | 2024-09-03 | Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20120115849A1 (https=) |
| EP (2) | EP2640395A4 (https=) |
| JP (9) | JP2014504271A (https=) |
| KR (8) | KR20230104760A (https=) |
| CN (3) | CN106038567A (https=) |
| AU (1) | AU2011326173B2 (https=) |
| BR (1) | BR112013011419B1 (https=) |
| CA (1) | CA2817071C (https=) |
| CL (1) | CL2013001136A1 (https=) |
| IL (1) | IL226203B (https=) |
| MX (2) | MX389018B (https=) |
| NZ (3) | NZ628055A (https=) |
| RU (1) | RU2661410C2 (https=) |
| WO (1) | WO2012064667A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106038567A (zh) | 2010-11-08 | 2016-10-26 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| AR084093A1 (es) * | 2010-12-03 | 2013-04-17 | Orexigen Therapeutics Inc | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica |
| IN2014DN10404A (https=) * | 2012-05-07 | 2015-08-14 | Omeros Corp | |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| TW201613590A (en) * | 2014-09-12 | 2016-04-16 | Purdue Pharma Lp | Systems and methods for attenuating opioid-induced euphoria |
| WO2016130043A1 (ru) * | 2015-02-13 | 2016-08-18 | Александ Васильевич ИВАЩЕНКО | Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в |
| CA2998868A1 (en) * | 2015-09-16 | 2017-03-23 | The Trustees Of Columbia University In The City Of New York | Carboxylic diarylthiazepineamines as mu-opioid receptor agonists |
| US10961244B2 (en) | 2016-03-25 | 2021-03-30 | The Trustees Of Columbia University In The City Of New York | Mitragynine alkaloids as opioid receptor modulators |
| JP7252908B2 (ja) | 2017-06-14 | 2023-04-05 | トレベナ・インコーポレイテッド | Ｓ１ｐ１活性を調節するための化合物およびその使用法 |
| US10220061B1 (en) | 2017-09-26 | 2019-03-05 | Cynthia Denapoli | Method of reducing stress and anxiety in equines |
| WO2020183350A1 (en) * | 2019-03-12 | 2020-09-17 | Radient Technologies Innovations Inc. | Transdermal patch kit with transdermal dosage units |
| AU2020341464A1 (en) * | 2019-09-05 | 2022-04-21 | Trevena, Inc. | Methods of treating epilepsy using the same |
| WO2021063388A1 (zh) * | 2019-09-30 | 2021-04-08 | 武汉大学 | c-Kit作为成瘾诊断及监测标志物和成瘾治疗靶点的应用 |
| MX2022005766A (es) | 2019-11-19 | 2022-08-08 | Trevena Inc | Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1). |
| CN111494383B (zh) * | 2020-06-04 | 2021-03-19 | 牡丹江医学院 | 一种预防和治疗酒精引起焦虑的药物组合物 |
| AU2022362107A1 (en) | 2021-10-11 | 2024-05-02 | Anebulo Pharmaceuticals, Inc. | Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof |
| WO2023064228A1 (en) * | 2021-10-11 | 2023-04-20 | Anebulo Pharmaceuticals, Inc. | Method of treating addiction |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20260048059A1 (en) | 2022-08-18 | 2026-02-19 | Klaus Wirth | Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intoleranc |
| US20260083736A1 (en) * | 2024-09-24 | 2026-03-26 | Boehringer Ingelheim International Gmbh | Ghrelin o-acyl transferase (goat) inhibitors for use in the treatment of substance use disorder in patients with high impulsivity |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| EP0306531A4 (en) | 1986-12-11 | 1989-04-12 | Toray Industries | FLEXIBLE THERMAL TRANSFER STRUCTURE AND PRODUCTION METHOD. |
| MC2115A1 (fr) | 1987-12-15 | 1991-07-05 | Gene Shears Pty Ltd | Ribozynes |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| EP0710106A4 (en) * | 1993-03-17 | 1999-07-21 | Pietr Hitzig | METHOD FOR TREATING ADDICTIVE BEHAVIOR |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| CN1045718C (zh) * | 1995-11-06 | 1999-10-20 | 西安天诚医药生物工程有限公司 | 青藤碱的医药新用途 |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| WO2000068230A1 (en) | 1999-05-05 | 2000-11-16 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors |
| AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
| US6146876A (en) | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
| PL197983B1 (pl) * | 1999-07-01 | 2008-05-30 | Upjohn Co | Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku |
| DE19950647A1 (de) | 1999-10-21 | 2001-04-26 | Merck Patent Gmbh | Imidazolderivate als Phosphodiesterase VII-Hemmer |
| US7491742B2 (en) | 1999-10-21 | 2009-02-17 | Merck Patent Gmbh | Imidazole derivatives as phosphodiesterase VII inhibitors |
| DE19953025A1 (de) | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Pyrrolderivate als Phosphodiesterase VII-Hemmer |
| DE19953024A1 (de) | 1999-11-04 | 2001-05-10 | Merck Patent Gmbh | Isoxazolderivate als Phosphodiesterase VII-Hemmer |
| DE19953414A1 (de) | 1999-11-06 | 2001-05-10 | Merck Patent Gmbh | Imidazopyridinderivate als Phospodiesterase VII-Hemmer |
| DE19954707A1 (de) | 1999-11-13 | 2001-05-17 | Merck Patent Gmbh | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| AU4415501A (en) | 2000-02-24 | 2001-09-03 | Bayer Aktiengesellschaft | Regulation of human gelatinase b-like enzyme 1 |
| GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
| GB0015095D0 (en) | 2000-06-20 | 2000-08-09 | Celltech Chiroscience Ltd | Chemical compounds |
| AU2001270205A1 (en) * | 2000-06-26 | 2002-01-08 | Applied Materials, Inc. | Method and apparatus for wafer cleaning |
| EP1193261A1 (en) | 2000-10-02 | 2002-04-03 | Warner-Lambert Company | New thiadiazoles and their use as phosphodiesterase-7 inhibitors |
| CZ20031334A3 (cs) | 2000-11-14 | 2003-09-17 | Altana Pharma Ag | Isochinolinové deriváty a jejich použití jako inhibitory |
| AU2002224835A1 (en) | 2000-11-14 | 2002-05-27 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Dihydroisoquinolines as novel phosphodiesterase inhibitors |
| US6617357B2 (en) | 2001-03-06 | 2003-09-09 | Smithkline Beecham Corporation | Compounds and their use as PDE inhibitors |
| AP1699A (en) | 2001-03-21 | 2006-12-26 | Warner Lambert Co | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| US6958328B2 (en) | 2001-04-18 | 2005-10-25 | Ortho-Mcneil Pharmaceutical, Inc | Arylindenopyridines and related therapeutic and prophylactic methods |
| US6903109B2 (en) | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
| CN1293074C (zh) | 2001-04-18 | 2007-01-03 | 奥索-麦克尼尔药品公司 | 具有pde抑制活性的芳基茚并吡啶 |
| EP1385848A2 (en) | 2001-04-25 | 2004-02-04 | ALTANA Pharma AG | Phtalazinones derivatives useful as pde4/7 inhibitors |
| MXPA03009925A (es) | 2001-04-30 | 2004-06-30 | Bayer Pharmaceuticals Corp | Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas. |
| US20030053980A1 (en) | 2001-04-30 | 2003-03-20 | The Gillette Company | Shaving compositions containing highly lubricious water soluble polymers |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
| HU228316B1 (en) | 2001-12-13 | 2013-03-28 | Daiichi Sankyo Company | Pyrazolopyrimidinone derivatives having pde7-inhibitory activity |
| DE10163991A1 (de) | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| WO2003057149A2 (en) | 2001-12-28 | 2003-07-17 | Bayer Corporation | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones |
| TW200302726A (en) | 2002-01-31 | 2003-08-16 | Ono Pharmaceutical Co | Nitrogen-containing bicyclic compound and medicament containing same as active ingredient |
| EP1348701A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors |
| EP1348433A1 (en) | 2002-03-28 | 2003-10-01 | Warner-Lambert Company LLC | Thiazol-2-yl-imine compounds as PDE-7 inhibitors |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| WO2004044196A1 (en) | 2002-11-13 | 2004-05-27 | Bayer Healthcare Ag | DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH HUMAN PHOSPHODIESTERASE 7B (PDE7b) |
| ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
| EP1631568A1 (en) * | 2003-04-18 | 2006-03-08 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| JP2006219374A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体 |
| JP2006219373A (ja) | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
| EP1668024A4 (en) | 2003-09-29 | 2008-07-02 | Topigen Pharma Inc | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INCLUDING INFLAMMATORY SUFFERING |
| US20080282364A1 (en) * | 2003-10-31 | 2008-11-13 | Shawn C Black | Phosphodiesterase 9 Inhibition as Treatment for Obesity-Related Conditions |
| WO2006004040A1 (ja) | 2004-07-01 | 2006-01-12 | Daiichi Asubio Pharma Co., Ltd. | Ｐｄｅ７阻害作用を有するチエノピラゾール誘導体 |
| RU2252038C1 (ru) * | 2004-07-30 | 2005-05-20 | Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук | Способ интерактивного лечения зависимого поведения |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| CA2599662A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of pde7 inhibitors for the treatment of neuropathic pain |
| WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| CA2623072A1 (en) * | 2005-09-26 | 2007-04-05 | Avigen, Inc. | Use of ibudilast for treating drug and behavioral addictions |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| RS20080233A (sr) | 2005-12-02 | 2009-07-15 | Pfizer Limited, | Derivati spirocikličnog hinazolina kao inhibitori pde7 |
| TW200734933A (en) * | 2006-03-06 | 2007-09-16 | Pixart Imaging Inc | Dot-matrix pattern design and decoding method and the device thereof |
| WO2007128884A1 (en) | 2006-05-09 | 2007-11-15 | Oy Jurilab Ltd | Novel genes and markers in type 2 diabetes and obesity |
| ES2308916B1 (es) | 2007-03-22 | 2009-10-29 | Consejo Superior De Investigaciones Cientificas | Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones. |
| JP5580192B2 (ja) * | 2007-03-27 | 2014-08-27 | オメロス コーポレーション | 運動障害の処置のためのｐｄｅ７インヒビターの使用 |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| US20100179158A1 (en) | 2007-04-20 | 2010-07-15 | Hoffman Charles S | Inhibitors of cyclic amp phosphodiesterases |
| US20100216823A1 (en) | 2007-05-24 | 2010-08-26 | Pfizer Inc. | Spirocyclic Derivatives |
| RU2351371C1 (ru) * | 2007-11-12 | 2009-04-10 | Ринат Равильевич Саберов | Способ лечения компульсивного обжорства |
| KR20150065941A (ko) | 2008-03-06 | 2015-06-15 | 아나코르 파마슈티칼스 인코포레이티드 | 소염제로써 붕소가 함유된 소분자 |
| EP2285384A4 (en) | 2008-05-12 | 2012-04-25 | Anacor Pharmaceuticals Inc | BORN SMALL MOLECULES |
| EP2348863A4 (en) | 2008-09-04 | 2012-03-07 | Anacor Pharmaceuticals Inc | BORN SMALL MOLECULES |
| EP2334180A4 (en) | 2008-09-15 | 2013-07-03 | Univ California | RESTRICTING DISEASES WITH A COMBINATION OF ACTIVE SUBSTANCES TO INCREASE THE CONCENTRATION OF EPOXYGENATED FATTY ACIDS AND ACTIVE SUBSTANCES TO INCREASE THE CAMP CONCENTRATION |
| EP2346867A1 (en) * | 2008-09-19 | 2011-07-27 | Ranbaxy Laboratories Limited | Phosphodiestarase inhibitors |
| FR2943673B1 (fr) | 2009-03-27 | 2013-03-29 | Sanofi Aventis | Applications therapeutiques de derives de quinazolinedione |
| FR2944282B1 (fr) | 2009-04-09 | 2013-05-03 | Sanofi Aventis | Derives de quinazolinedione, leur preparation et leurs diverses applications therapeutiques |
| CN106038567A (zh) | 2010-11-08 | 2016-10-26 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
| US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
| IN2014DN10404A (https=) | 2012-05-07 | 2015-08-14 | Omeros Corp |
-
2011
- 2011-11-07 CN CN201610333696.9A patent/CN106038567A/zh active Pending
- 2011-11-07 RU RU2013126476A patent/RU2661410C2/ru active
- 2011-11-07 CN CN201180064354.7A patent/CN103547267A/zh active Pending
- 2011-11-07 CN CN201710717548.1A patent/CN107375296A/zh active Pending
- 2011-11-07 KR KR1020237021889A patent/KR20230104760A/ko not_active Ceased
- 2011-11-07 EP EP11840549.7A patent/EP2640395A4/en not_active Withdrawn
- 2011-11-07 MX MX2018001236A patent/MX389018B/es unknown
- 2011-11-07 KR KR1020177034857A patent/KR20170136020A/ko not_active Ceased
- 2011-11-07 EP EP23191932.5A patent/EP4275752A3/en active Pending
- 2011-11-07 CA CA2817071A patent/CA2817071C/en active Active
- 2011-11-07 KR KR1020187025325A patent/KR102054899B1/ko active Active
- 2011-11-07 WO PCT/US2011/059626 patent/WO2012064667A2/en not_active Ceased
- 2011-11-07 NZ NZ628055A patent/NZ628055A/en unknown
- 2011-11-07 KR KR1020247043441A patent/KR20250007057A/ko active Pending
- 2011-11-07 BR BR112013011419-3A patent/BR112013011419B1/pt active IP Right Grant
- 2011-11-07 US US13/290,868 patent/US20120115849A1/en not_active Abandoned
- 2011-11-07 NZ NZ628054A patent/NZ628054A/en unknown
- 2011-11-07 KR KR1020167024095A patent/KR20160105948A/ko not_active Ceased
- 2011-11-07 AU AU2011326173A patent/AU2011326173B2/en active Active
- 2011-11-07 KR KR1020197036066A patent/KR102385359B1/ko active Active
- 2011-11-07 JP JP2013537915A patent/JP2014504271A/ja active Pending
- 2011-11-07 MX MX2013004943A patent/MX2013004943A/es unknown
- 2011-11-07 KR KR1020137014793A patent/KR20130124333A/ko not_active Ceased
- 2011-11-07 KR KR1020227011477A patent/KR20220047894A/ko not_active Ceased
- 2011-11-07 NZ NZ610925A patent/NZ610925A/en unknown
-
2013
- 2013-04-25 CL CL2013001136A patent/CL2013001136A1/es unknown
- 2013-05-07 IL IL226203A patent/IL226203B/en active IP Right Grant
-
2015
- 2015-01-09 JP JP2015002909A patent/JP2015071648A/ja active Pending
-
2016
- 2016-05-12 JP JP2016095809A patent/JP2016145255A/ja not_active Withdrawn
-
2018
- 2018-01-05 JP JP2018000537A patent/JP2018048213A/ja not_active Withdrawn
- 2018-01-15 US US15/871,768 patent/US11207275B2/en active Active
-
2019
- 2019-03-26 JP JP2019058230A patent/JP2019094352A/ja active Pending
-
2020
- 2020-11-02 JP JP2020183616A patent/JP2021014461A/ja not_active Withdrawn
-
2021
- 2021-11-18 US US17/530,011 patent/US20220062194A1/en not_active Abandoned
-
2022
- 2022-08-17 JP JP2022130095A patent/JP2022159477A/ja not_active Withdrawn
-
2023
- 2023-12-15 JP JP2023212021A patent/JP2024015430A/ja active Pending
-
2024
- 2024-09-03 JP JP2024151513A patent/JP2024170507A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024015430A5 (https=) | ||
| RU2009141615A (ru) | Композиции и способы профилактики и лечения зависимости | |
| RU2013126476A (ru) | Лечение зависимости и расстройства побуждений с применением ингибиторов фдэ7 | |
| JP2010523718A5 (https=) | ||
| CA2519556A1 (en) | Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same | |
| US7968119B2 (en) | Tamper-proof narcotic delivery system | |
| JP2006524261A5 (https=) | ||
| JP2011515495A5 (https=) | ||
| JP2010189403A5 (https=) | ||
| AU2003234395B2 (en) | Abuse-resistant opioid solid dosage form | |
| CA2699172C (en) | Compositions and methods for delivery of poorly soluble drugs | |
| RU2009101082A (ru) | Фармацевтические композиции | |
| CA2557839A1 (en) | Tamper resistant dosage form comprising an adsorbent and an adverse agent | |
| JP2009541320A5 (https=) | ||
| HRP20100289T1 (hr) | Proizvodi otporni na miješanje za opioidnu primjenu | |
| CA2456601A1 (en) | Oral dosage form comprising a therapeutic agent and an adverse-effect agent | |
| JP2009529046A5 (https=) | ||
| JP2012519675A5 (https=) | ||
| JP2009545561A5 (https=) | ||
| SG191872A1 (en) | Pharmaceutical composition comprising opioid agonist and sequestered antagonist | |
| CA2640339A1 (en) | Tamper resistant opioid dosage forms | |
| RU2011135568A (ru) | Защищенная от применения не по назначению экструдированная из расплава композиция с уменьшенным взаимодействием со спиртом | |
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| RU2017112301A (ru) | Стойкие к злоупотреблению фармацевтические композиции | |
| CA2652981A1 (en) | Robust sustained release formulations |